350-05A
Human Coronary Artery Smooth Muscle Cells: HCASMC, adult
Sinônimo(s):
HCASMC cells
About This Item
fonte biológica
human coronary artery (normal, tunica intima and media)
Nível de qualidade
embalagem
pkg of 500,000 cells
fabricante/nome comercial
Cell Applications, Inc
modo de crescimento
Adherent
cariótipo
2n = 46
morfologia
smooth muscle
técnica(s)
cell culture | mammalian: suitable
doença(s) relevante(s)
diabetes; stroke; cardiovascular diseases
Condições de expedição
dry ice
temperatura de armazenamento
−196°C
Descrição geral
Human Coronary Artery Smooth Muscle Cells (HCASMC) provide an excellent model system to study all aspects of cardiovascular function and disease, especially those related to mechanisms of hyperplasia and hypertrophy of intimal smooth muscle cells leading to vascular occlusion in atherosclerosis and stent restenosis.
HCASMC has been utilized in a number of research studies, for example, to:
- Study signaling pathways regulating smooth muscle differentiation (Zhou, 2010); and chronic inflammation of arterial wall that leads to artherosclerosis (Kiyan, 2014)
- Demonstrate that STAT-1 and STAT-3 regulate VEGF production in smooth muscle cells by having opposing effects on HIF-1α expression (Albasanz-Puig, 2012); study the mechanisms of hypoxia and reoxigenation injuries in by demonstrating increased production of ROS and inflammatory cytokines, and further showing that DHA is not beneficial in this type of injuries (Feng, 2012)
- Investigate the gene expression differences between smooth muscle cells from different arteries, underlying their differential response to injuries and proliferation stimuli (Lange, 2013)
- Suggest the hypermethylation of SOCS3 gene as the connection between TNF-α and IGF-1 released in response to mechanical injury during coronary intervention, and the induction of cytokines leading to intimal hyperplasia and restenosis (Dhar, 2013)
- Develop a novel VEGFR/MET-targeted inhibitor with improved antitumor efficacy and decreased toxicity (Fujita, 2013); and investigate novel therapies and drug combinations to achieve optimal target selectivity (Lehar, 2009; Wo-Wong, 2013)
- Develop elastic scaffolds for tissue engineering (Nivison-Smith, 2010, 2012) and novel treatment strategies to prevent stent restenosis by designing new materials (Crowder, 2012), or drug therapies to preferentially inhibit smooth muscle cell growth (O’Neill, 2009; Mociornita, 2013)
Characterization: positive for smooth muscle cell specific alpha-actin expression.
Origem de linhagem celular
Aplicação
Componentes
Nota de preparo
- 2nd passage, >500,000 cells in Basal Medium containing 10% FBS & 10% DMSO
- Can be cultured at least 16 doublings
Rotina de subcultura
Exoneração de responsabilidade
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Certificados de análise (COA)
Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Os clientes também visualizaram
Artigos
Technical information for working with human coronary artery smooth muscle cells including thawing, subculturing and cryopreservation
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica